PKBSM6556DJTO

not provided

human beta cell line

EndoC-bH1 cells treated with IL-1b for 24hr from GSE235683

DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, fatty acid free, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100U/mL penicillin + 100 μg/mL streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, treated with 50 U/mL Interleukin-1 beta for 86400 seconds

Homo sapiens

PKBSM3533XIDS

human beta cell line

EndoC-bH1 cells treated with conditioned media from HEK293 cells expressing empty vector (EV) from GSE185430

DMEM LG (glucose 1 g/l), BSA fraction V (2% wt/vol), β-mercaptoethanol (50 μM), nicotinamide (10 mM), transferrin (5.5 μg/ml), sodium selenite (6.7 ng/ml), and penicillin–streptomycin (1%).

EndoC-bH1

released

EndoC-βH1 cell line, depleted of HEK293

Homo sapiens

PKBSM9187LZBV

human beta cell line

EndoC-bH1 cells transduced with empty lentivirus GSE236102

DMEM low glucose supplemented with 2% bovine serum albumin (BSA), 50 μM β-mercaptoethanol, 1% GlutaxMAX, 10 mM nicotinamide, 5.5 μg/mL human transferrin, and 6.7 ng/mL sodium selenite

EndoC-bH1

released

EndoC-βH1 cell line, depleted of lentiCRISPRv2

Homo sapiens

PKBSM2973NJDC

human beta cell line

EndoC-bH1 cells treated with NLRC5 siRNA and IFNa for 8hr from GSE202852

Dulbecco’s modified Eagle medium with 5.6 mM glucose, 2% fatty acid–free BSA fraction V, 50 μM 2-mercaptoethanol, 10 mM nicotinamide, transferrin, selenite (6.7 ng/ml), and penicillin (100 U/ml) + streptomycin (100 μg/ml)

EndoC-bH1

released

EndoC-βH1 cell line, depleted of NLRC5 for 8 hours, treated with 2000 U/mL Interferon alpha for 8 hours

Homo sapiens

PKBSM6845SNYE

human beta cell line

EndoC-bH2 cells treated with extreme hyperglycemia from GSE212749

DMEM low glucose (1g/L), 2% Albumin from bovine serum fraction V, 50μM 2-mercaptoethanol, 10mM nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL sodium selenite and Penicillin (100 units/mL)/Streptomycin (100 μg/mL)

EndoC-bH2

released

EndoC-bH2 cell line, treated with 35 mM Glucose for 72 hours

Homo sapiens

PKBSM0561GQKP

human beta cell line

EndoC-bH3 cells treated with 4-hydroxy tamoxifen for three weeks from GSE207816

DMEM low glucose (1 g/L) supplemented with 2% fatty acid free BSA , 10 mM nicotinamide, 5.5 µg/mL human transferrin, 6.7 ng/mL sodium selenite, 50 µM β-mercaptoethanol, 100 U/mL penicillin and 100 µg/mL streptomycin

EndoC-bH3

released

EndoC-bH3 cell line, treated with 1 mM 4-hydroxy tamoxifen for 21 days

Homo sapiens

PKBSM5212UTHG

not provided

human beta cell line

EndoC-bH1 cells treated with TNFa for 24hr from GSE235683

DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, fatty acid free, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100U/mL penicillin + 100 μg/mL streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, treated with 1000 U/mL Tumor necrosis factor for 86400 seconds

Homo sapiens

PKBSM6750EOBQ

human beta cell line

EndoC-bH1 cells treated with SRRM3 siRNA for 72hr from GSE198906

DMEM that contained 5.6 mM glucose, 2% BSA fraction V, 50 μM 2-mercaptoethanol, 10 mM nicotinamide, 5.5 μg/ml transferrin, 6.7 ng/ml selenite, 100 U/ml penicillin, and 100 μg/ml streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, depleted of SRRM3

Homo sapiens

PKBSM5416TOEI

human beta cell line

EndoC-bH1 cells treated with METTL14 siRNA from GSE132306

DMEM (glucose 1 g/L), BSA fraction V (2% wt/vol), 2-mercaptoethanol (50 μM), nicotinamide (10 mM), transferrin (5.5 μg/mL), sodium selenite (6.7 ng/mL), PS (1%)

EndoC-bH1

released

EndoC-βH1 cell line, depleted of METTL14

Homo sapiens

PKBSM0734OIDU

not provided

human beta cell line

EndoC-bH1 cells treated with Dexamethasone for 24hr from GSE225901

DMEM containing 5.6 mM glucose, 2% BSA fraction V , 10 mM nicotinamide, 50 μM 2-mercaptoethanol, 5.5 μg/mL transferrin, 6.7 ng/mL sodium selenite, 100 U/mL penicillin, and 100 μg/mL streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, treated with 2 μM dexamethasone for 86400 seconds

Homo sapiens

PKBSM8133OGIJ

human beta cell line

EndoC-bH1 cells treated with negative control siRNA from GSE162837

DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100 units/mL penicillin, and 100 μg/mL streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, depleted of negative control siRNA

Homo sapiens

PKBSM8660JQFD

human beta cell line

EndoC-bH1 cells treated with control siRNA from GSE98485

DMEM that contained 5.6 mM glucose, 2% BSA fraction V , 50 μM 2-mercaptoethanol, 10 mM nicotinamide, 5.5 μg/ml transferrin, 6.7 ng/ml selenite, 100 U/ml penicillin, and 100 μg/ml streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, depleted of negative control siRNA

Homo sapiens

PKBSM6207TNSY

human beta cell line

EndoC-bh1 cells treated with T-antigen (460) siRNA and stable expression of SIX2 from GSE79469

DMEM that contained 5.6 mM glucose, 2% BSA fraction V, 50 μM 2-mercaptoethanol, 10 mM nicotinamide, 5.5 μg/ml transferrin, 6.7 ng/ml selenite, 100 U/ml penicillin, and 100 μg/ml streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, depleted of SIX2

Homo sapiens

PKBSM2550NVQO

human beta cell line

EndoC-bh1 cells treated with conditioned media from TNFa-treated omental stromal cells from GSE184795

low-glucose DMEM medium (5.6 mmol/L) supplemented with 2% BSA fraction V , 50 μM β-mercaptoethanol, 10 mM nicotinamide, 5.5 μg/mL human transferrin, 6.7 ng/mL selenite, 100 U/mL penicillin and 100 μg/mL streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, depleted of TNF

Homo sapiens

PKBSM4462KSYC

human beta cell line

EndoC-bh1 cells treated with T-antigen (2046) siRNA and stable expression of SIX3 from GSE79469

DMEM that contained 5.6 mM glucose, 2% BSA fraction V, 50 μM 2-mercaptoethanol, 10 mM nicotinamide, 5.5 μg/ml transferrin, 6.7 ng/ml selenite, 100 U/ml penicillin, and 100 μg/ml streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, depleted of SIX3

Homo sapiens

PKBSM8514OGUP

human beta cell line

EndoC-bH3 cells treated with A1CF sgRNA and CRISPR-Cas9 RNPs from GSE277551

Advanced DMEM/F12 supplemented with 2% fatty acid-free Bovine Serum Albumin Fraction V, 6.7 ng/mL sodium selenite, 50 μM 2-mercaptoethanol, 5.5 μg/mL human transferrin, 10 mM nicotinamide, 1% GlutaMAX and 100 U/mL Penicillin-Streptomycin

EndoC-bH3

released

EndoC-bH3 cell line, depleted of A1CF, Cas9 RNP

Homo sapiens

PKBSM2497EGUQ

human beta cell line

EndoC-bH1 cells treated with SPOCK2 overexpression vector from GSE190361

Dulbecco’s modified Eagle’s medium containing 1g/L glucose (DMEM) supplemented with 2% BSA fraction V fatty acid free, 50 μM 2-mercaptoethanol, 10 mM nicotinamide, 5.5 μg/ml transferrin, 6.7 ng/ml selenite, 100 U/ml penicillin, and 100 μg/ml streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, depleted of SPOCK2

Homo sapiens

PKBSM9444BMDZ

human beta cell line

Test Human Beta Cell Lines

CMRL-1066 medium supplemented with 10% FBS and 1% penicillin streptomycin

EndoC-Bh1

released

B cell line

Homo sapiens

PKBSM6804KICF

human beta cell line

EndoC-bH1 cells treated with non-targeting control shRNA from GSE190361

Dulbecco’s modified Eagle’s medium containing 1g/L glucose (DMEM) supplemented with 2% BSA fraction V fatty acid free, 50 μM 2-mercaptoethanol, 10 mM nicotinamide, 5.5 μg/ml transferrin, 6.7 ng/ml selenite, 100 U/ml penicillin, and 100 μg/ml streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, depleted of non-targeting shRNA

Homo sapiens

PKBSM9024KLYK

human beta cell line

EndoC-bh1 cells treated with conditioned media from omental stromal cells from GSE184795

low-glucose DMEM medium (5.6 mmol/L) supplemented with 2% BSA fraction V , 50 μM β-mercaptoethanol, 10 mM nicotinamide, 5.5 μg/mL human transferrin, 6.7 ng/mL selenite, 100 U/mL penicillin and 100 μg/mL streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, depleted of stromal cell

Homo sapiens

PKBSM2542NXUU

human beta cell line

EndoC-bH1 cells treated with control siRNA and IFNa for 24hr from GSE202852

Dulbecco’s modified Eagle medium with 5.6 mM glucose, 2% fatty acid–free BSA fraction V, 50 μM 2-mercaptoethanol, 10 mM nicotinamide, transferrin, selenite (6.7 ng/ml), and penicillin (100 U/ml) + streptomycin (100 μg/ml)

EndoC-bH1

released

EndoC-βH1 cell line, depleted of negative control siRNA for 24 hours, treated with 2000 U/mL Interferon alpha for 24 hours

Homo sapiens

PKBSM3112HPHH

human beta cell line

EndoC-bH2 cells treated with hyperglycemia from GSE212749

DMEM low glucose (1g/L), 2% Albumin from bovine serum fraction V, 50μM 2-mercaptoethanol, 10mM nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL sodium selenite and Penicillin (100 units/mL)/Streptomycin (100 μg/mL)

EndoC-bH2

released

EndoC-bH2 cell line, treated with 20 mM Glucose for 72 hours

Homo sapiens

PKBSM6822XTNL

human beta cell line

EndoC-bH1 cells treated with STAT3 siRNA from GSE162837

DMEM containing 5.6 mmol/L glucose, 2% BSA fraction V, 50 μmol/L 2-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/mL transferrin, 6.7 ng/mL selenite, 100 units/mL penicillin, and 100 μg/mL streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, depleted of STAT3

Homo sapiens

PKBSM3992LBEW

human beta cell line

EndoC-bH1 cells treated with IFNg and IL1b for 48hr from GSE137136

DMEM medium (no other details provided)

EndoC-bH1

released

EndoC-βH1 cell line, treated with 1000 U/mL Interleukin-1 beta for 48 hours, 50 U/mL Interferon gamma for 48 hours

Homo sapiens

PKBSM1534PVXT

human beta cell line

EndoC-bH1 cells treated with control siRNA for 72hr from GSE182016

Dulbecco's modified Eagle's medium (5,6 mmol/l) supplemented with 2% bovine serum albumin (BSA) fraction V , 50 μmol/L 2-β-mercaptoethanol, 10 mmol/L nicotinamide, 5.5 μg/ml transferrin, 6.7 ng/ml sodium selenite, 100 units/ml penicillin, and 100 μg/ml streptomycin

EndoC-bH1

released

EndoC-βH1 cell line, depleted of negative control siRNA for 72 hours

Homo sapiens